HOME >> BIOLOGY >> NEWS
New Hope On The Horizon For Patients With End-Stage Cardiovascular Disease

LOS ANGELES (August 3, 1998) -- Two experimental protocols are now available at Cedars-Sinai Medical Center for patients who have undergone multiple angioplasties or bypass procedures for coronary artery disease. Both procedures are non-surgical and show promise of improving quality of life for patients with end-stage cardiovascular disease. "The preliminary data are very encouraging," says P.K. Shah, M.D., Director of Cardiology at Cedars-Sinai.

Percutaneous Transmyocardial Laser Revascularization (PTMR)
According to Dr. Shah, Cedars-Sinai is one of only a few sites in the nation to offer Percutaneous Transmyocardial Laser Revascularization (PTMR). Using this procedure, cardiologists insert a laser catheter into the heart, creating multiple channels from the inside of the heart, out. These channels improve blood flow to heart muscles and stimulate growth of new blood vessels. To date, four patients have undergone PTMR at Cedars-Sinai. Norman Lepor, M.D., is the Principal Investigator on this study.

Vascular Endothelial Growth Factor Therapy (VEGF)
The second experimental protocol is Vascular Endothelial Growth Factor (VEGF) Therapy. VEGF is a genetically engineered compound that is normally produced in small amounts by the body and stimulates blood vessel growth. In this procedure, it is injected directly into the coronary artery to further stimulate blood vessel growth. The initial injection is followed by a series of three intravenous infusions -- one every three days. These subsequent infusions are done on an outpatient basis and take about four hours each. To date, two patients have been treated with VEFG Therapy at Cedars-Sinai. Dr. Shah is the Principal Investigator on this study.

# # #

To arrange an interview, please call 1-800-396-1002. Reporters, please note that this telephone number is exclusively for media use. Thank you for not publishing it.


'"/>

Contact: Sandy Van or Roberta Nichols
sandy@vancommunications.com
1-800-396-1002
Cedars-Sinai Medical Center
3-Aug-1998


Page: 1

Related biology news :

1. Bacteria Becoming Increasingly Resistant To Antibiotics, But New Vaccines Are On The Horizon
2. Patients cells from tumors, the immune system merged for customized cancer therapy
3. Patients give nod to kidney dialysis at home
4. Patients with atrial fibrillation undertreated for stroke risk
5. Patients with serious kidney disorder produce natriuretic peptides at above average rates
6. Drug treatment interruptions boost immune response to HIV in Patients
7. Study Suggests Vaccine Increases Survival In Ovarian And Breast Cancer Patients Following High-Dose Chemotherapy And Autologous Stem Cell Transplant
8. GenRISK Genetic Testing Program At Cedars-Sinai Medical Center Offers Patients New Hope In Confronting Disease
9. Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders
10. In Colorado States Veterinary Foal Care Program, Student Volunteers Provide All-Night Care For Sick And Very Needy Patients
11. AIDS Virus May Evolve Differently In Cerebrospinal Fluid Compared With Blood In Some Patients, UCSF/Gladstone Research Finds

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
Breaking Biology Technology:
Cached News: